Cargando…

Dynamic changes and multiplication rate of white blood cell count may direct the timing of cytoreduction chemotherapy during induction treatment in newly diagnosed acute promyelocytic leukemia with low-intermediate risk

In order to explore the optimal timing for initiating cytoreduction chemotherapy following all-trans retinoic acid plus arsenic trioxide administration, 58 newly diagnosed patients with acute promyelocytic leukemia (APL) with low-intermediate mortality risk were retrospectively analyzed. During indu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wen, Jingjing, Xu, Fang, Zhou, Qiaolin, Hu, Hong, Liu, Yiping, Su, Jing, Zhang, Ya, Qu, Wen, Shi, Lin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8060852/ https://www.ncbi.nlm.nih.gov/pubmed/33903818 http://dx.doi.org/10.3892/mco.2021.2274

Ejemplares similares

Predictors of early death and clinical features in newly diagnosed patients with low-intermediate risk acute promyelocytic leukemia
por: Wen, Jingjing, et al.
Publicado: (2022)

Effects of peripheral blood leukocyte count and tumor necrosis factor-alpha on early death in acute promyelocytic leukemia
por: Wen, Jingjing, et al.
Publicado: (2023)

Hypertriglyceridemia in Newly Diagnosed Acute Promyelocytic Leukemia
por: Sun, Jianai, et al.
Publicado: (2020)

Newly Diagnosed Acute Promyelocytic Leukemia
por: Avvisati, Giuseppe
Publicado: (2011)

A rare case of acute promyelocytic leukemia with IRF2BP2-RARA fusion; and literature review
por: Liu, Yiping, et al.
Publicado: (2019)

Treatment of Acute Promyelocytic Leukemia with High White Cell Blood Counts.
por: Kelaidi, C., et al.
Publicado: (2011)

Low platelet count is potentially the most important contributor to severe bleeding in patients newly diagnosed with acute promyelocytic leukemia
por: Song, Yu-hua, et al.
Publicado: (2017)

Analysis of early death in newly diagnosed acute promyelocytic leukemia patients
por: Xu, Fang, et al.
Publicado: (2017)

Cost-effectiveness of the regimen proposed by the International Consortium on Acute Promyelocytic Leukemia for the treatment of newly diagnosed patients with Acute Promyelocytic Leukemia
por: Rodríguez-Rodríguez, Sergio, et al.
Publicado: (2021)

Institutional factors associated with early mortality of newly diagnosed acute promyelocytic leukemia
por: Matsuda, Kensuke, et al.
Publicado: (2022)

Intracranial Hemorrhage Secondary to Newly Diagnosed Acute Promyelocytic Leukemia: A Cautionary Tale
por: Peddi, Kanksha, et al.
Publicado: (2022)

Influence of cytokines on early death and coagulopathy in newly diagnosed patients with acute promyelocytic leukemia
por: Zhao, Shixiang, et al.
Publicado: (2023)

Efficacy and safety analysis of bortezomib-based triplet regimens sequential lenalidomide in newly diagnosed multiple myeloma patients
por: Zhou, Qiaolin, et al.
Publicado: (2022)

Additional cytogenetic abnormalities in patients with newly diagnosed acute promyelocytic leukemia predict inferior event‐free survival
por: Zeng, Hui, et al.
Publicado: (2023)

Retrospective Study of Acute Kidney Injury Incidence in Patients with Newly Diagnosed Acute Promyelocytic Leukemia
por: Kamio, Tadashi, et al.
Publicado: (2020)

Prompt Initiation of Conventional Chemotherapy to Avoid Early Death in Patients with Newly Diagnosed Acute Promyelocytic Leukemia
por: Matsuda, Kensuke, et al.
Publicado: (2022)

Comparison of Newly Diagnosed and Relapsed Patients with Acute Promyelocytic Leukemia Treated with Arsenic Trioxide: Insight into Mechanisms of Resistance
por: Chendamarai, Ezhilarasi, et al.
Publicado: (2015)

Consolidation therapy of arsenic trioxide alternated with chemotherapy achieves remarkable efficacy in newly diagnosed acute promyelocytic leukemia
por: Liu, Cheng-cheng, et al.
Publicado: (2015)

Expression of CD56 is an unfavorable prognostic factor for acute promyelocytic leukemia with higher initial white blood cell counts
por: Ono, Takaaki, et al.
Publicado: (2014)

Gemtuzumab ozogamicin plus standard induction chemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia
por: Awada, Hassan, et al.
Publicado: (2023)

Induction treatments for acute promyelocytic leukemia: a network meta-analysis
por: Huang, Junjie, et al.
Publicado: (2016)

Apoptosis Induction by Menadione in Human Promyelocytic Leukemia HL-60 Cells
por: Sa, Duck-Jin, et al.
Publicado: (2009)

Complications during Induction Chemotherapy in Acute Promyelocytic Leukemia: An Institutional Experience
por: Yedla, Rajani Priya, et al.
Publicado: (2022)

Oral etoposide combined with oral arsenic plus retinoic acid for two cases with newly diagnosed high-risk acute promyelocytic leukemia during COVID19 pandemic
por: Lu, Sheng-ye, et al.
Publicado: (2021)

Acute Promyelocytic Leukemia
por: Thomas, Xavier, et al.
Publicado: (2020)

Induction of Apoptosis in Human Promyelocytic Leukemia HL60 Cells by Panaxynol and Panaxydol
por: Yan, Zhonghong, et al.
Publicado: (2011)

Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia
por: Cherry, Evan M., et al.
Publicado: (2021)

Combination of cyclophosphamide and cytarabine as induction regimen for newly diagnosed adult acute myeloid leukemia
por: Liu, Qingguo, et al.
Publicado: (2020)

Significance of ETV6 rearrangement in acute promyelocytic leukemia with t(15;17)/promyelocytic leukemia/retinoic acid receptor alpha
por: GAO, NA, et al.
Publicado: (2016)

Results of Phase 1 study on cytoreductive radical prostatectomy in men with newly diagnosed metastatic prostate cancer
por: Yuh, Bertram E., et al.
Publicado: (2019)

History of Acute Promyelocytic Leukemia
por: Sanz, Miguel A., et al.
Publicado: (2021)

PB1851: EARLY DEATHS IN PATIENTS WITH NEWLY DIAGNOSED ACUTE PROMYELOCYTIC LEUKEMIA: A SINGLE-CENTER RETROSPECTIVE STUDY FROM A GENERAL HOSPITAL
por: Yohannan, B., et al.
Publicado: (2022)

Acute promyelocytic leukemia with normal karyotype initially diagnosed on bone marrow touch imprints
por: Park, Joowon
Publicado: (2015)

Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group
por: Adès, Lionel, et al.
Publicado: (2018)

Bradycardia during Induction Therapy with All-trans Retinoic Acid in Patients with Acute Promyelocytic Leukemia: Case Report and Literature Review
por: Chen, Pin-Zi, et al.
Publicado: (2018)

Bayesian network meta-analysis comparing five contemporary treatment strategies for newly diagnosed acute promyelocytic leukaemia
por: Wu, Fenfang, et al.
Publicado: (2016)

Standard-Intensity Induction and Intermediate/High-Dose Cytarabine Consolidation Can Improve Survival for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: A Retrospective Cohort Study
por: Wang, Li, et al.
Publicado: (2022)

Differentiation syndrome-induced Myopericarditis in the induction therapy of acute Promyelocytic leukemia: a case report
por: Shenoy, Shabari Mangalore, et al.
Publicado: (2021)

Arsenic toxicity manifesting as profuse watery diarrhea during induction therapy for acute promyelocytic leukemia
por: Ott, Ashley, et al.
Publicado: (2021)

Acute promyelocytic leukemia with unusual karyotype
por: Gowri, Mangala, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_i1llvshgrejr910576okdo5jps